Covered recipient · General Payments record
LORELEI M SUNDERLAND
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$661.30
- Reported across 36 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $321.05 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $155.13 | 8 |
| Amgen Inc. | $54.07 | 3 |
| Otsuka America Pharmaceutical, Inc. | $39.26 | 2 |
| Novo Nordisk AS | $31.28 | 2 |
| CeQur Corporation | $27.88 | 1 |
| GlaxoSmithKline, LLC. | $13.43 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $16.13 | 02/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117695591 | CMS |
| Amgen Inc. | $21.64 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117695593 | CMS |
| Amgen Inc. | $16.30 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117695595 | CMS |
| CeQur Corporation | $27.88 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1099648879 | CMS |
| GlaxoSmithKline, LLC. | $13.43 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116000451 | CMS |
| Lilly USA, LLC | $17.86 | 01/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135768265 | CMS |
| Lilly USA, LLC | $17.95 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135795842 | CMS |
| Lilly USA, LLC | $23.96 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135753611 | CMS |
| Lilly USA, LLC | $16.89 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135795840 | CMS |
| Lilly USA, LLC | $19.07 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135797754 | CMS |
| Lilly USA, LLC | $28.38 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135804030 | CMS |
| Lilly USA, LLC | $13.21 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135741564 | CMS |
| Lilly USA, LLC | $17.81 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135795844 | CMS |
| Novo Nordisk Inc | $15.22 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100393884 | CMS |
| Novo Nordisk Inc | $16.06 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100386435 | CMS |
| Otsuka America Pharmaceutical, Inc. | $21.88 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119195584 | CMS |
| Otsuka America Pharmaceutical, Inc. | $17.38 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119195586 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.